Scholarlink

Purpose <p>De novo oligometastatic breast cancer (OMBC) is often defined as up to five metastases in two or fewer organs at presentation. Studies have suggested favorable outcomes for patients with OMBC; however, management remains controversial. We analyzed outcomes of patients with de novo OMBC treated with physician-expressed curative intent at a single institution.</p> Methods <p>We identified patients by performing a keyword search for terms of interest within institutional electronic medical records. We defined OMBC as four or fewer metastases in one organ. Primary surgery was required for inclusion in the analytic cohort. Recurrence-free survival (RFS) and overall survival (OS) were evaluated using Kaplan–Meier methods.</p> Results <p>Thirty-nine patients were identified: 12 hormone receptor-positive (HR+)/HER2+ , 2 HR-negative (HR-)/HER2-, 21 HR+ /HER2-, and 4 HR-/HER2+ . Thirty-three patients (84.6%) had 1 metastasis at diagnosis. Median age was 47&#xa0;years (28–69). Twenty-nine patients (74.4%) underwent adjuvant radiation to the breast. Two-thirds of patients underwent metastasis-directed therapy. Five-year OS was 77% (95% CI 61–95%). Median RFS was 7.1&#xa0;years (95% CI 4.62-not reached). Five-year RFS was 58% (95% CI 42–81%).</p> Conclusions <p>Survival outcomes were favorable among this select cohort. Optimal treatment for de novo OMBC remains unclear. Curative intent trials are underway for HER2+ de novo OMBC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution

  • 期刊论文

  • 发表日期：

    2026年1月8日

查看全文
  • Emily L. Chen,
  • Hillary Heiling,
  • Tianyu Li,
  • Jennifer R. Bellon,
  • Faina Nakhlis,
  • Heather A. Parsons,
  • Alyssa Martin,
  • Harold J. Burstein,
  • Sara M. Tolaney,
  • Craig Snow,
  • Nabihah Tayob,
  • Lior Z. Braunstein,
  • Nancy U. Lin,
  • Sarah Sammons

摘要

Purpose

De novo oligometastatic breast cancer (OMBC) is often defined as up to five metastases in two or fewer organs at presentation. Studies have suggested favorable outcomes for patients with OMBC; however, management remains controversial. We analyzed outcomes of patients with de novo OMBC treated with physician-expressed curative intent at a single institution.

Methods

We identified patients by performing a keyword search for terms of interest within institutional electronic medical records. We defined OMBC as four or fewer metastases in one organ. Primary surgery was required for inclusion in the analytic cohort. Recurrence-free survival (RFS) and overall survival (OS) were evaluated using Kaplan–Meier methods.

Results

Thirty-nine patients were identified: 12 hormone receptor-positive (HR+)/HER2+ , 2 HR-negative (HR-)/HER2-, 21 HR+ /HER2-, and 4 HR-/HER2+ . Thirty-three patients (84.6%) had 1 metastasis at diagnosis. Median age was 47 years (28–69). Twenty-nine patients (74.4%) underwent adjuvant radiation to the breast. Two-thirds of patients underwent metastasis-directed therapy. Five-year OS was 77% (95% CI 61–95%). Median RFS was 7.1 years (95% CI 4.62-not reached). Five-year RFS was 58% (95% CI 42–81%).

Conclusions

Survival outcomes were favorable among this select cohort. Optimal treatment for de novo OMBC remains unclear. Curative intent trials are underway for HER2+ de novo OMBC.